| Sachem Center For Health & Rehabilitation | |
| 66 Central Street, East Bridgewater, Massachusetts 02333 | |
| (508) 378-7227 | |
| Name | Sachem Center For Health & Rehabilitation |
|---|---|
| Location | 66 Central Street, East Bridgewater, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 111 |
| Occupancy Rate | 72.79% |
| Medicare ID (CCN) | 225322 |
| Legal Business Name | Vk East Bridgewater Llc |
| Ownership Type | For Profit - Partnership |
| NPI Number | 1073853560 |
| Organization Name | VK EAST BRIDGEWATER, LLC |
| Doing Business As | SACHEM CENTER FOR HEALTH & REHABILITATION |
| Address | 66 Central St, East Bridgewater, MA 02333 |
| Phone Number | 508-378-7227 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
According to new visual perception research from a team at Boston University, the use of boldly colored tableware is a mealtime aid to those with severe AD, helping individuals overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
› Verified 7 days ago
| NPI Number | 1114226677 |
| Organization Name | PEOPLEFIRSTREHAB |
| Address | 66 Central St, East Bridgewater, MA 02333 |
| Phone Number | 508-378-7227 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
According to new visual perception research from a team at Boston University, the use of boldly colored tableware is a mealtime aid to those with severe AD, helping individuals overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
› Verified 7 days ago
| NPI Number | 1376257956 |
| Organization Name | ADVINIACARE EAST BRIDGEWATER LLC |
| Address | 66 Central St, East Bridgewater, MA 02333 |
| Phone Number | 781-255-0531 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
According to new visual perception research from a team at Boston University, the use of boldly colored tableware is a mealtime aid to those with severe AD, helping individuals overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
According to new visual perception research from a team at Boston University, the use of boldly colored tableware is a mealtime aid to those with severe AD, helping individuals overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $64194 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 23.02 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 4.74 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 59.79 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.52 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.01 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 2.45 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 99.65 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 19.5 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.41 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.13 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 28.13 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.39 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 2.99 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 95.99 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.77 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 94.07 | 82.93 |
News Archive
CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious disease, is pleased to announce that an Investigational New Drug application (IND) for Neutrolin was submitted to the United States Food and Drug Administration on Wednesday, September 24, 2014.
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
According to new visual perception research from a team at Boston University, the use of boldly colored tableware is a mealtime aid to those with severe AD, helping individuals overcome a diminished sensitivity to visual contrast, a condition often found among people with advanced AD.
In what may prove to be a major step forward for the treatment of HIV-1 infection, scientists have discovered an effective way to eliminate a notoriously persistent form of the virus that does not respond to current therapies. The research, published online by Cell Press on March 8th from the journal Immunity, describes a vaccination strategy that may be essential for successful eradication efforts and should therefore be considered for future clinical trials.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced results from the MAGELLAN Phase 3 trial evaluating the investigational oral anticoagulant rivaroxaban for the prevention of venous thromboembolism in hospitalized patients with acute medical illnesses.
› Verified 7 days ago
Sachem Center For Health & Rehabilitation Location: 66 Central Street, East Bridgewater, Massachusetts 02333 Phone: (508) 378-7227 |